SEC Form	4
----------	---

Instruction 1(b).

## FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average bu	urden
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

			of Section 50(n) of the investment Company Act of 1940				
1. Name and Address of Reporting Person <sup>*</sup> Chopas James George			2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Apellis Pharmaceuticals, Inc.</u> [ APLS ]		ationship of Reporting Pe (all applicable) Director	10% Owner	
(Last) C/O APELLIS	(First) (Middle) PHARMACEUTICALS, INC.		3. Date of Earliest Transaction (Month/Day/Year) 01/22/2024	X	Officer (give title below) VP/Chief Accountin	Other (specify below) ting Officer	
100 FIFTH AVENUE, 3RD FLOOR			4. If Amendment, Date of Original Filed (Month/Day/Year)	<i>v</i> idual or Joint/Group Fili			
			_	X	Form filed by One Reporting Person		
(Street) WALTHAM	MA	02451			Form filed by More th Person	an One Reporting	
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication				
			Check this box to indicate that a transaction was made pursuant satisfy the affirmative defense conditions of Rule 10b5-1(c). See			an that is intended to	
		Table I - Non-Deriv	vative Securities Acquired. Disposed of. or Bene	ficially	Owned		

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (		Disposed Of	isposed Of (D) (Instr. 3, 4 and b) (D) (Instr. 3, 4 and b) (D) or Inc (I) (Instr. 2) (D) or Inc (I) (Instr. Reported Transaction(s)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price			(1150.4)
Common Stock	01/22/2024		<b>S</b> <sup>(1)</sup>		1,061	D	\$64.996	39,067	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

·					-												
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Deriv	r osed ) r. 3, 4	6. Date Exerc Expiration Da (Month/Day/Y	ate	Amou Secu Unde Deriv	rities rlying ative rity (Instr.	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						

Explanation of Responses:

1. This represents shares sold to cover tax withholding on the Restricted Stock Units released on 01/19/2024.

/s/ David Watson, attorney-in-01/23/2024 fact for James Chopas

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.